Edition:
India

Lannett Company Inc (LCI.N)

LCI.N on New York Stock Exchange

16.80USD
21 Feb 2018
Change (% chg)

$0.50 (+3.07%)
Prev Close
$16.30
Open
$16.40
Day's High
$17.45
Day's Low
$16.40
Volume
71,572
Avg. Vol
142,583
52-wk High
$30.35
52-wk Low
$14.95

Latest Key Developments (Source: Significant Developments)

Lannett Appoints Timothy Crew As CEO
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Lannett Company Inc ::LANNETT APPOINTS TIMOTHY C. CREW AS CEO.LANNETT COMPANY INC - TIMOTHY CREW WILL SUCCEED ARTHUR BEDROSIAN, WHO WILL CONTINUE TO SERVE AS CEO UNTIL CREW JOINS COMPANY.LANNETT COMPANY INC - BOARD NAMED TIMOTHY C. CREW AS CHIEF EXECUTIVE OFFICER, EFFECTIVE JANUARY 2, 2018.  Full Article

Lannett Reports FDA Acceptance Of 505(B)(2) NDA For Cocaine Hydrochloride Topical Solution
Friday, 1 Dec 2017 

Dec 1 (Reuters) - Lannett Company Inc ::LANNETT ANNOUNCES FDA ACCEPTANCE OF 505(B)(2) NEW DRUG APPLICATION FOR COCAINE HYDROCHLORIDE TOPICAL SOLUTION, A PROPRIETARY ANESTHETIC PRODUCT.LANNETT COMPANY - ‍FDA HAS ASSIGNED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE OF JULY 21, 2018, TEN MONTHS FROM OFFICIAL NDA SUBMISSION DATE​.  Full Article

Lannett Announces Agreement For Authorized Generic Version Of Toprol-XL
Thursday, 30 Nov 2017 

Nov 29 (Reuters) - Lannett Company Inc ::LANNETT ANNOUNCES AGREEMENT FOR AUTHORIZED GENERIC VERSION OF TOPROL-XL®.LANNETT COMPANY INC - FINANCIAL TERMS WERE NOT DISCLOSED..LANNETT COMPANY INC - HAS ENTERED INTO AN AGREEMENT WITH ARALEZ PHARMACEUTICALS TRADING DAC.LANNETT COMPANY - ‍AGREEMENT WITH ARALEZ PHARMACEUTICALS TRADING DAC TO BECOME EXCLUSIVE DISTRIBUTOR IN U.S. OF AUTHORIZED GENERIC VERSION OF TOPROL-XL​.LANNETT COMPANY INC - DEAL TO BECOME EXCLUSIVE DISTRIBUTOR IN U.S. OF TOPROL-XL EXTENDED RELEASE TABLETS IN 25 MG, 50 MG, 100 MG AND 200MG.  Full Article

Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Lannett Company Inc :Lannett reports solid fiscal 2018 first-quarter financial results, significantly increases fiscal 2018 guidance.Q1 adjusted earnings per share $0.60.Q1 earnings per share $0.35.Q1 earnings per share view $0.52 -- Thomson Reuters I/B/E/S.Q1 sales $155 million versus I/B/E/S view $153.6 million.Lannett Company Inc sees fiscal 2018 ‍net sales of $710 million to $720 million, up from $655 million to $665 million​.Lannett Company Inc sees fiscal 2018 ‍capital expenditures of $65 million to $75 million.Q1 revenue view $153.6 million -- Thomson Reuters I/B/E/S.FY2018 revenue view $658.6 million -- Thomson Reuters I/B/E/S.  Full Article

Deerfield Management LP reports 8.28% passive stake in Lannett Co as of Oct 25, 2017-SEC filing‍​
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Deerfield Management L.P: :Deerfield Management LP reports a 8.28 percent passive stake in Lannett Company Inc as of October 25, 2017-SEC filing‍​.  Full Article

Lannett Co calls price fixing allegations about a single product named in complaint that co sells "meritless"
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Lannett Company Inc :Lannett Company Inc - ‍comments on amended civil generic drug price-fixing complaint ​.Lannett - believe price-fixing allegations about a single product named in complaint that co sells are "meritless​".  Full Article

Lannett and Celgene enter into settlement and license agreement related to Thalomid
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Celgene Corp :Lannett and Celgene enter into settlement and license agreement related to Thalomid.Lannett - ‍subject to FDA approval of co's ANDA for thalidomide, co intends to launch product under terms of license agreement, which are confidential​.Lannett-‍license agreement permits co to manufacture, market in U.S. generic thalidomide product as of Aug 1, 2019 or earlier under certain circumstances​.  Full Article

Lannett Q4 adjusted earnings per share $0.73
Wednesday, 24 Aug 2016 

Lannett Company Inc : Lannett announces record net sales for fiscal 2016 fourth-quarter and full-year . Q4 adjusted earnings per share $0.73 . Q4 earnings per share $0.10 . Q4 sales $168.9 million versus i/b/e/s view $161.6 million . Q4 earnings per share view $0.59 -- Thomson Reuters I/B/E/S . Lannett Company Inc Sees fiscal 2017 capital expenditures $55 million to $65 million . Lannett Company Inc sees FY 2017 net sales to be between $690 million and $700 million . Lannett company inc sees fiscal 2017 gaap gross margin percentage 50% to 51% .Lannett Company Inc sees fiscal 2017 adjusted gross margin percentage 55% to 56%.  Full Article

Lannett provides update on application for generic Fentanyl patch
Wednesday, 20 Jul 2016 

Lannett Company Inc : Lannett announces receipt of FDA Acceptable for Filing letter for Fentanyl Patch ANDA . Under agreement, Sparsha Pharma USA will manufacture product and Lannett will be responsible for distribution .Strategic partner, Sparsha Pharma USA Inc, has received an acceptable for filing letter from FDA for Fentanyl Patch ANDA.  Full Article

Lannett company announces approval, launch for Paroxetine Extended Release Tablets USP
Monday, 11 Jul 2016 

Lannett Company Inc : Lannett announces approval and launch of Paroxetine Extended Release Tablets USP, 12.5 mg, 25 mg, 37.5 mg ."Fiscal 2017, which began on July 1, 2016, is currently exceeding our expectations".  Full Article

BRIEF-Lannett Company Files For Potential Mixed Shelf Offering

* LANNETT COMPANY INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING Source text: (http://bit.ly/2GblSC4) Further company coverage: